Biotech Small-Cap Looks to Rival Pfizer With Rare Disease Drug
This article is for subscribers only.
A small-cap biotechnology firm that took part in a red-hot summer for going public thinks its lead drug can compete with industry heavy-weights like Pfizer Inc.
Eidos Therapeutics Inc. is set to release results from a mid-stage study of its drug for a rare, deadly disease in coming months. Investors will be looking for good news: shares dropped some 30 percent since just after going public less than two months ago.